FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311093072> ?p ?o ?g. }

• W4311093072 endingPage "B028" @default.
• W4311093072 startingPage "B028" @default.
• W4311093072 abstract "Abstract Introduction: BRAF + EGFR inhibition induces decreased expression of mismatch repair (MMR) genes in preclinical models of microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer (mCRC) but has not been reported in patients. We evaluated exosomal RNA (exoRNA) isolated from serial blood specimens collected from patients (pts) with MSS, BRAFV600E mCRC treated with encorafenib (E) + cetuximab (C) + nivolumab (N) as a novel blood-based approach to compare differences in gene expression according to treatment response. Methods: Pts with refractory MSS, BRAFV600E mCRC were treated with E (300 mg daily), C (500 mg/m2 q2 weeks), and N (480 mg q4 weeks) on an IRB-approved clinical trial at MD Anderson. Responses to treatment were assessed every 8 weeks (RECIST v1.1). ExoRNA isolated from pretreatment and on-treatment (week 8) blood samples were sequenced (SMART-seq) and deconvoluted (DeMix) in order to estimate cancer-specific gene expression. Previously validated MAPK and interferon (IFN)-γ gene expression signatures were used for measuring transcriptomic changes following treatment with E+C+N. Scores between responders and non-responders were compared by unpaired t-tests. For Gene Set Enrichment Analysis (GSEA), an adjusted false discovery rate (FDR) &lt; 0.25 was applied to find significantly enriched pathways between on-treatment and pretreatment samples separately for responders and non-responders. Results: 26 pts were treated with E+C+N, and 24 were evaluable for response. Overall response rate was 50% (95% confidence interval (CI), 29-71), and median progression-free survival was 7.4 months (95% CI, 6.0-NA). Four pts remained on study &gt; 12 months. Between responders vs non-responders (N=12 each), mean changes in MAPK signature score was decreased (-0.63 vs 0.15, respectively; p=.13). Both patients with response &gt; 18 months demonstrated dramatic increases in IFN-γ score following treatment with E+C+N (+13.1 and +14.6), a trend not observed in all other patients (range, -18.0 to 3.6). Among responders to E+C+N, GSEA analysis demonstrated dynamic pathway changes in normalized enrichment score (NES) for DNA repair (NES -2.3; p-adj=.008), IL6/JAK/STAT3 (NES -2.1, p-adj=.02), and IFN-α response (NES -2.0, p-adj=.03). For non-responders, relative increases in NES were observed for angiogenesis (NES 2.1, p-adj=.02) and IL-2/STAT5 (NES 2.0, p-adj= .02). Conclusions: Transcriptome analysis using exoRNA isolated from serial blood samples is feasible for assessing treatment response in pts with mCRC. Decreased MAPK score in exoRNA may be associated with treatment response to E+C+N in pts with MSS, BRAFV600E mCRC. Changes in immune NES scores following treatment may distinguish responders from non-responders to MAPK + PD-1 blockade and highlight targets for novel immune-mediated combinations for MSS, BRAFV600E mCRC. Citation Format: Van Karlyle Morris, Kimal I. Rajapakshe, Vahid Bahrambeigi, Christine M. Parsehgian, Benny Johnson, Kanwal P. Raghav, Arvind Dasari, Ryan W. Huey, Michael J. Overman, Jason Willis, Michael S. Lee, Robert A. Wolff, Bryan K. Kee, Phat Le, Paola A. Guerrero, Scott Kopetz, Anirban Maitra. Changes in exosomal RNA expression associate with treatment response to BRAF + EGFR + PD-1 blockade in MSS, BRAFV600E colorectal cancer: A liquid biopsy approach [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1):Abstract nr B028." @default.
• W4311093072 created "2022-12-23" @default.
• W4311093072 creator A5003827387 @default.
• W4311093072 creator A5010363210 @default.
• W4311093072 creator A5010668711 @default.
• W4311093072 creator A5015321333 @default.
• W4311093072 creator A5021608539 @default.
• W4311093072 creator A5028897969 @default.
• W4311093072 creator A5035371911 @default.
• W4311093072 creator A5041593227 @default.
• W4311093072 creator A5060749148 @default.
• W4311093072 creator A5062779886 @default.
• W4311093072 creator A5064181876 @default.
• W4311093072 creator A5064540759 @default.
• W4311093072 creator A5064548744 @default.
• W4311093072 creator A5069877747 @default.
• W4311093072 creator A5076410221 @default.
• W4311093072 creator A5088195904 @default.
• W4311093072 creator A5089710556 @default.
• W4311093072 date "2022-12-01" @default.
• W4311093072 modified "2023-09-24" @default.
• W4311093072 title "Abstract B028: Changes in exosomal RNA expression associate with treatment response to BRAF + EGFR + PD-1 blockade in MSS, BRAFV600E colorectal cancer: A liquid biopsy approach" @default.
• W4311093072 doi "https://doi.org/10.1158/1538-7445.crc22-b028" @default.
• W4311093072 hasPublicationYear "2022" @default.
• W4311093072 type Work @default.
• W4311093072 citedByCount "0" @default.
• W4311093072 crossrefType "journal-article" @default.
• W4311093072 hasAuthorship W4311093072A5003827387 @default.
• W4311093072 hasAuthorship W4311093072A5010363210 @default.
• W4311093072 hasAuthorship W4311093072A5010668711 @default.
• W4311093072 hasAuthorship W4311093072A5015321333 @default.
• W4311093072 hasAuthorship W4311093072A5021608539 @default.
• W4311093072 hasAuthorship W4311093072A5028897969 @default.
• W4311093072 hasAuthorship W4311093072A5035371911 @default.
• W4311093072 hasAuthorship W4311093072A5041593227 @default.
• W4311093072 hasAuthorship W4311093072A5060749148 @default.
• W4311093072 hasAuthorship W4311093072A5062779886 @default.
• W4311093072 hasAuthorship W4311093072A5064181876 @default.
• W4311093072 hasAuthorship W4311093072A5064540759 @default.
• W4311093072 hasAuthorship W4311093072A5064548744 @default.
• W4311093072 hasAuthorship W4311093072A5069877747 @default.
• W4311093072 hasAuthorship W4311093072A5076410221 @default.
• W4311093072 hasAuthorship W4311093072A5088195904 @default.
• W4311093072 hasAuthorship W4311093072A5089710556 @default.
• W4311093072 hasConcept C121608353 @default.
• W4311093072 hasConcept C126322002 @default.
• W4311093072 hasConcept C143998085 @default.
• W4311093072 hasConcept C2777701055 @default.
• W4311093072 hasConcept C2779984678 @default.
• W4311093072 hasConcept C2779998722 @default.
• W4311093072 hasConcept C2780030458 @default.
• W4311093072 hasConcept C2780739268 @default.
• W4311093072 hasConcept C3019894029 @default.
• W4311093072 hasConcept C31760486 @default.
• W4311093072 hasConcept C526805850 @default.
• W4311093072 hasConcept C535046627 @default.
• W4311093072 hasConcept C71924100 @default.
• W4311093072 hasConcept C90924648 @default.
• W4311093072 hasConceptScore W4311093072C121608353 @default.
• W4311093072 hasConceptScore W4311093072C126322002 @default.
• W4311093072 hasConceptScore W4311093072C143998085 @default.
• W4311093072 hasConceptScore W4311093072C2777701055 @default.
• W4311093072 hasConceptScore W4311093072C2779984678 @default.
• W4311093072 hasConceptScore W4311093072C2779998722 @default.
• W4311093072 hasConceptScore W4311093072C2780030458 @default.
• W4311093072 hasConceptScore W4311093072C2780739268 @default.
• W4311093072 hasConceptScore W4311093072C3019894029 @default.
• W4311093072 hasConceptScore W4311093072C31760486 @default.
• W4311093072 hasConceptScore W4311093072C526805850 @default.
• W4311093072 hasConceptScore W4311093072C535046627 @default.
• W4311093072 hasConceptScore W4311093072C71924100 @default.
• W4311093072 hasConceptScore W4311093072C90924648 @default.
• W4311093072 hasIssue "23_Supplement_1" @default.
• W4311093072 hasLocation W43110930721 @default.
• W4311093072 hasOpenAccess W4311093072 @default.
• W4311093072 hasPrimaryLocation W43110930721 @default.
• W4311093072 hasRelatedWork W1963973664 @default.
• W4311093072 hasRelatedWork W2116448148 @default.
• W4311093072 hasRelatedWork W2120490763 @default.
• W4311093072 hasRelatedWork W2729289325 @default.
• W4311093072 hasRelatedWork W2768563229 @default.
• W4311093072 hasRelatedWork W3026015583 @default.
• W4311093072 hasRelatedWork W3133969996 @default.
• W4311093072 hasRelatedWork W4292087709 @default.
• W4311093072 hasRelatedWork W4292696415 @default.
• W4311093072 hasRelatedWork W4292801102 @default.
• W4311093072 hasVolume "82" @default.
• W4311093072 isParatext "false" @default.
• W4311093072 isRetracted "false" @default.
• W4311093072 workType "article" @default.